First-in-Human Study of STX-478, a Mutant-Selective PI3Kα Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
This clinical trial is testing a new experimental medicine called STX-478, both on its own and combined with other cancer drugs. The study aims to find the safest and most effective dose for treating advanced solid tumors and hormone receptor-positive breast cancer that have a specific genetic change.
Adults aged 18 and older with advanced solid tumors or hormone receptor-positive breast cancer that has a specific PI3Kalpha genetic mutation may be able to join. Participants need to be well enough to handle daily activities and provide a recent tumor tissue sample.
Depending on the study part you join, you will receive the experimental drug STX-478 either by itself or combined with standard hormone therapies and other cancer-fighting medications. Your health team will carefully monitor you throughout the process, starting with a 28-day screening period.
This study is currently recruiting participants at multiple locations, including sites in Los Angeles and San Francisco, California, as well as Aurora, Colorado.
- 1Testing an experimental targeted cancer treatment called STX-478
- 2Options include taking the study drug alone or combined with existing cancer therapies
- 3Open to adults with advanced solid tumors and specific genetic mutations
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.